Abstract
Background - Inhibition of leukocyte adhesion can reduce myocardial infarct size in animals. This study was designed to define the safety and efficacy of a recombinant, humanized, monoclonal antibody to the CD18 subunit of the β2 integrin adhesion receptors (rhuMAb CD18), in reducing infarct size in patients treated with a thrombolytic agent. Methods and Results - The Limitation of Myocardial Infarction following Thrombolysis in Acute Myocardial Infarction Study (LIMIT AMI) was a randomized, double-blind, placebo-controlled, multicenter study conducted in 60 centers in the United States and Canada. A total of 394 subjects who presented within 12 hours of symptom onset with ECG findings (ST-segment elevation) consistent with AMI were treated with recombinant tissue plasminogen activator and were also given an intravenous bolus of 0.5 or 2.0 mg/kg rhuMAb CD18 or placebo. Coronary angiography was performed at 90 minutes, 12-lead ECGs were obtained at baseline, 90, and 180 minutes, and resting sestamibi scans were performed at ≥ 120 hours. Adjunctive angioplasty and use of glycoprotein IIb/IIIa antiplatelet agents at the time of angiography were discretionary. There were no treatment effects on coronary blood flow, infarct size, or the rate of ECG ST-segment elevation resolution, despite the expected induction of peripheral leukocytosis. A slight trend toward an increase in bacterial infections was observed with rhuMAb CD18 (P = 0.33). Conclusions - RhuMAb CD18 was well tolerated but not effective in modifying cardiac end points.
Original language | English (US) |
---|---|
Pages (from-to) | 2778-2783 |
Number of pages | 6 |
Journal | Circulation |
Volume | 104 |
Issue number | 23 |
DOIs | |
State | Published - Dec 4 2001 |
Keywords
- Antibodies
- Cell adhesion molecules
- Inflammation
- Myocardial infarction
- Trials
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)